犬尿氨酸代谢通路中重度抑郁障碍的潜在生物标记物研究

Research on the Potential Biomarkers of Major Depression Disorder in Kynurenine Metabolism Pathway

目的探讨犬尿氨酸代谢通路中重度抑郁症(major depression disorder,MDD)的潜在生物标记物。方法分别收集20例健康志愿者及20例MDD住院患者入院和出院时的血清样本,采用LC-MS/MS法测定血清中色氨酸、犬尿氨酸和犬尿喹啉酸的浓度。采用配对t检验,分析MDD患者入院和出院时上述指标的差异;采用单因素方差分析,分别比较健康志愿者和MDD患者入院时、健康志愿者和MDD患者出院时上述指标的差异。结果健康志愿者、MDD患者入院和出院时色氨酸水平分别为(12 091.73±1 703.84),(12 982.74±2 641.26)和(13 136.02±3 119.17) ng·mL-1,犬尿氨酸水平分别为(328.25±86.23),(257.72±74.28)和(304.72±85.62)ng·mL-1,犬尿喹啉酸水平分别为(4.10±1.50),(3.79±1.57)和(3.89±1.92) ng·mL-1。其中,健康志愿者和MDD患者入院时、MDD患者入院和出院时比较,犬尿氨酸水平差异均有统计学意义(P<0.05);健康志愿者和MDD患者出院时比较,犬尿氨酸水平差异无统计学意义(P>0.05)。结论提示犬尿氨酸可能为MDD的潜在生物标记物,为临床MDD患者的诊断和治疗提供参考依据。

OBJECTIVE To explorer the potential biomarkers of major depression disorder(MDD) in the kynurenine metabolic pathway. METHODS Serum samples were collected from 20 healthy volunteers and 20 inpatients with MDD at the time of admission and discharge,and the concentrations of tryptophan,kynurenineand kynurenic acid in serum were determined by high performance liquid tandem mass spectrometry.The paired t-test was used to analyze the differences of concentrations of above indexes at the time of admission and discharge of inpatients with MDD. The One-way analysis of variance was used to compare the differences in the above indexes between healthy volunteers and patients at the time of admission and discharge. RESULTS The average values of tryptophan for healthy volunteers,patients at the time of admission and dischargewere(12 091.73±1 703.84),(12 982.74±2 641.26) and(13 136.02±3 119.17)ng·mL-1,respectively. And the corresponding values for kynurenine were(328.25±86.23),(257.72±74.28),(304.72±85.62)ng·mL-1,respectively. The kynurenic acid were(4.10±1.50),(3.79±1.57),(3.89±1.92)ng·mL-1,respectively. Significant difference in kynurenine levels were found between inpatientsat the time of admission and discharge,and between healthy volunteers and patients at admission(P<0.05),but no significant difference was abserved in kynurenine levels between healthy volunteers and patients when discharged(P>0.05). CONCLUSION It is suggested that kynurenine may be used as a potential biomarker of MDD and the results can provide reference for the diagnosis and treatment of patients with MDD.